IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting | Zendy

MaríaCarlota Londoño | Zendy; Christian Manzardo | Zendy; Antoni Rimola | Zendy; Pablo Ruíz | Zendy; Josep Costa | Zendy; Alejandro Forner | Zendy; Juan Ambrosioni | Zendy; Fernando Agüero | Zendy; Montserrat Laguno | Zendy; Anna Lligoña | Zendy; Asunción Moreno | Zendy; J. M. Miró | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting

Author(s) -

MaríaCarlota Londoño,

Christian Manzardo,

Antoni Rimola,

Pablo Ruíz,

Josep Costa,

Alejandro Forner,

Juan Ambrosioni,

Fernando Agüero,

Montserrat Laguno,

Anna Lligoña,

Asunción Moreno,

J. M. Miró

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw270

Subject(s) - medicine , tolerability , sofosbuvir , gastroenterology , hepatitis c , ribavirin , hepatocellular carcinoma , liver transplantation , cirrhosis , adverse effect , population , decompensation , liver function , transplantation , hepatitis c virus , immunology , virus , environmental health

IFN-based therapy against hepatitis C recurrence after liver transplantation (LT) has poor effectiveness and tolerability. In HIV/HCV-coinfected liver transplant recipients, the results are even poorer. Here, we report our experience using direct antiviral agents (DAAs) in 11 consecutive coinfected patients within the LT setting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research